Fact Source: Financial Supervisory Service DART / 2025-01-22
Disclosure Type: Large-Scale Corporate Variance in Sales or Profit/Loss Structure (Over 15%)
💡 3-Second Summary
SAMSUNG BIOLOGICS’ full-year 2024 consolidated revenue expanded by 23.1% year-over-year to approximately KRW 4.55T, and operating profit grew by 18.5% to KRW 1.32T, driven by the stable operations of Plants 1-3 and the successful production ramp-up of Plant 4.
📊 1. [Key Disclosure Content & Major Figures Summary]
- Consolidated Profit/Loss Structure Variance (Unit: KRW):
- Revenue: KRW 4,547,322,176,000 (KRW 4.547T / +23.1% year-over-year)
- Operating Profit: KRW 1,320,052,380,000 (KRW 1.320T / +18.5% year-over-year)
- Income Before Income Tax Expenses: KRW 1,370,051,626,000 (KRW 1.370T / +22.3% year-over-year)
- Net Income: KRW 1,083,315,886,000 (KRW 1.083T / +26.3% year-over-year)
- Consolidated Financial Condition (Unit: KRW):
- Total Assets: KRW 17,336,296,350,000 (KRW 17.336T)
- Total Liabilities: KRW 6,431,620,287,000 (KRW 6.432T)
- Total Equity (Controlling Interest Same): KRW 10,904,676,062,000 (KRW 10.905T)
- Capital Stock: KRW 177,935,000,000 (KRW 177.9B)
- Total Equity to Capital Stock Ratio: 6,128.5% (Increased from 5,524.8% in the prior fiscal year)
- Separate Financial Metric (Unit: KRW):
- Revenue: KRW 3,497,145,676,000 (KRW 3.497T)
- Primary Causes of Variance: Continuous stable operation of Plants 1 through 3, paired with an increasing top-line contribution from the successful utilization ramp-up of Plant 4.
- Board of Directors Resolution Date: January 22, 2025 (4 independent directors attended, 0 absent)
- Regulatory Caveat: These performance metrics constitute tentative internal financial statements prior to the completion of the external audit and are subject to change. Investors are advised to cross-reference these numbers with the subsequent formal ‘Submission of Audit Report’ filing.
📈 2. [Expert Insight: What This Disclosure Means for Investors]
This mandatory disclosure for large-scale corporations documents that SAMSUNG BIOLOGICS’ FY2024 annualized performance acceleration is driven by core manufacturing asset optimization rather than external variables, verifying the structural health of the company’s fundamental.
The primary fundamental takeaway is the formalized operational cause: the successful utilization ramp-up of Plant 4. In the capital-intensive CDMO sector, new facility rollouts typically introduce structural margin compression risks due to substantial upfront depreciation and fixed operational overhead. Defying this standard cycle by delivering concurrent high growth in both consolidated revenue (23.1%) and operating profit (18.5%) signals that Plant 4 has efficiently minimized its pre-operative loss window. Data validation checks out precisely, with full-year revenue comfortably scaling above the net operating profit lines.
Analyzing the financial safety metrics reveals a substantial expansion in the total equity-to-capital stock ratio to 6,128.5%. Retaining annualized net yields directly inside the corporate balance sheet fortifies the capital structure. This internal capital accumulation enhances the company’s strategic capacity to finance upcoming multi-billion dollar capital expenditures (CAPEX), such as the scheduled construction of Plant 5, primarily through organic cash flow rather than relying heavily on higher-cost external debt markets. While these internal figures remain tentative pending the finalized external audit review, the unanimous board confirmation denotes a stable trajectory for annualized milestone modeling.
📝 Editor’s Comment (by K-STOCK Editor)
SAMSUNG BIOLOGICS has officially cataloged the operational drivers behind its stellar FY2024 performance metrics. The top-line contribution of Plant 4 is now a documented accounting metric, proving that the facility has managed to counter typical pre-operating cost drags to firmly anchor the consolidated operating profit base at the KRW 1.32T level.
Watching the equity-to-capital ratio scale past 6,100% underscores the accumulation of capital strength on the balance sheet. This fortress layout provides management with organic funding to execute upcoming CAPEX expansions, including Plant 5, without relying heavily on debt financing. While these numbers are tentative pending the final external audit report, the structural layout demonstrates clear operational scaling, providing international institutional investors with a transparent baseline to track long-term backlog conversion.
📢 Disclaimer and Source Information
Source: This content was newly structured and written based on official data submitted to the Financial Supervisory Service’s Electronic Disclosure System (DART).
Investment Risk Notice: This information is provided solely for informational and linguistic reference purposes. Under no circumstances does it constitute financial advice or a recommendation to buy or sell specific stocks. All investment decisions and financial responsibilities rest entirely with the investor.
Contact: For compliance inquiries or copyright requests, please contact ksb220805@gmail.com.
🔥 Bulls vs Bears, drop your analysis in the comments!
